摘要
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitorsJournal of HepatologyVol. 68Issue 6PreviewImmune-modulatory therapies have dramatically improved the survival of patients with metastatic tumours.1,2 During the development of cancer, the immune system becomes naturally ‘tolerant’ towards cancer cells, which are seen as part of the ‘self’. This tolerance is maintained by immune checkpoint pathways that downregulate immune functions, permitting cancer cells to evade immune attacks.3,4 Monoclonal antibodies (mAbs) directed against regulatory immune checkpoint molecules that inhibit T cell activation enhance antitumour immunity. Full-Text PDF Reply to: “Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?”Journal of HepatologyVol. 69Issue 2PreviewWe thank Gauci and colleagues for their interest in our paper “Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors”1. Full-Text PDF We read with interest the recent report of liver damage caused by monoclonal immune checkpoint inhibitors published by De Martin et al.[1]De Martin E. Michot J.-M. Papouin B. Champiat S. Mateus C. Lambotte O. et al.Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.J Hepatol. 2018; 68: 1181-1190Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar Checkpoint inhibitors such as anti-programmed cell death 1 (PD-1) (pembrolizumab, nivolumab), anti-PD ligand 1 (PD-L1) (avelumab, durvalumab and atezolizumab) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) (ipilimumab) antibodies have revolutionized cancer treatment especially in melanoma,2Larkin J. Chiarion-Sileni V. Gonzalez R. Grob J.J. Cowey C.L. Lao C.D. et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med. 2015; 373: 23-34Crossref PubMed Scopus (5112) Google Scholar, 3Hodi F.S. O’Day S.J. McDermott D.F. Weber R.W. Sosman J.A. Haanen J.B. et al.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010; 363: 711-723Crossref PubMed Scopus (11191) Google Scholar, 4Robert C. Long G.V. Brady B. Dutriaux C. Maio M. Mortier L. et al.Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med. 2015; 372: 320-330Crossref PubMed Scopus (4027) Google Scholar, 5Robert C. Schachter J. Long G.V. Arance A. Grob J.J. Mortier L. et al.Pembrolizumab vs. ipilimumab in advanced melanoma.N Engl J Med. 2015; 372https://doi.org/10.1056/NEJMoa1503093Crossref Scopus (4051) Google Scholar by the restoration of functional T cell responses, yielding tumor destruction by the immune system and improved clinical outcomes. These drugs have a distinct toxicity profile with immune-related side effects including liver toxicities. De Martin et al.[1]De Martin E. Michot J.-M. Papouin B. Champiat S. Mateus C. Lambotte O. et al.Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.J Hepatol. 2018; 68: 1181-1190Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar reported clinical, biological and histological immune-related grade ≥3 hepatitis characteristics in 16 patients treated with anti-PD-1/PD-L1 and anti-CTLA4 monoclonal antibodies, in monotherapy or in combination, for various cancers. Management of these hepatoxicities particularly caught our attention. In this cohort, six patients (38%) did not receive any corticosteroid therapy and experienced a spontaneous improvement in liver tests. No ≥grade 3 hepatitis was observed after reintroduction of immunotherapy in two patients. The authors discussed the need for a patient-oriented management, which contrasts with current guidelines, and could eventually avoid useless systemic corticosteroid therapy. Spontaneous resolution of immune-related hepatitis was also reported for six patients.[7]Bernardo S.G. Moskalenko M. Pan M. Shah S. Sidhu H.K. Sicular S. et al.Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.Melanoma Res. 2013; 23: 47-54Crossref PubMed Scopus (40) Google Scholar We would like to report our experience on this important topic, as we had the opportunity to perform a retrospective analysis of all immune-related hepatitis that occurred in our center from October 2010 to May 2015. Among 128 patients treated for advanced melanoma with immune checkpoint inhibitors, 10 (7.8%) patients experienced immune-related hepatitis (Table S1). Median age was 55 years (range 36–80). There was no history of alcohol consumption, but one patient presented with resolved viral C hepatitis and two had pre-existing hepatic steatosis. Six patients were treated with anti-CTLA4, three patients with anti-PD-1 and one with the combination of anti-CTLA4 and anti-PD-1. One, seven and two patients experienced grade 2, grade 3 and grade 4 aminotransferase increase, respectively. Median time from the first infusion of immunotherapy to immune-related hepatitis onset was 9.9 weeks (range 2.9–19.7): 9.9 weeks (6.1–14.7) for anti-CTLA4, 14.1 weeks (9.4–19.7) for anti-PD-1 and 2.9 weeks for the combination. No patient experienced liver failure or toxicity-related death. Median peak aminotransferase level was 416 IU/L (range 155–1,735). Total bilirubin level increase was observed for four patients, but was only above 50 µmol/L in three patients. Median total bilirubin level was 76 µmol/L (range 4–160). The prothrombin time was normal for all patients. No patient presented autoantibody positivity except one: anti-mitochondrial antibody was positive at 1/1,600 with an aspect of primary biliary cholangitis at liver biopsy. Liver biopsy was performed in three patients and identified features of primary biliary cholangitis in one patient, and granulomatous hepatitis associated with a moderate and polymorphous inflammatory infiltrate, without interface hepatitis in the other two patients. For all patients, immunotherapy was discontinued because of the hepatic events. Ipilimumab was resumed in one patient, and another checkpoint inhibitor (from ipilimumab to nivolumab) was introduced in four patients without immune-related hepatitis relapse. Regarding immune-related hepatitis management, only half (five) of our patients received steroids:•Two patients were included in clinical trial and managed according to the trials recommendations•One patient received steroids for concomitant severe colitis•One patient was already on steroids for cerebral metastasis•One patient with concomitant diagnosis of primary biliary cholangitis was treated with ursodeoxycholic acid and low dose steroids (0.3 mg/kg/day) Hepatitis resolved in all five patients, and none needed a second-line treatment for the hepatic event. The other five patients, in accordance with the hepatologist’s recommendation, did not receive any steroids but were monitored for clinical and biological evolution. Interestingly, resolution of the adverse events was observed in all cases, with a median time of 4.7 weeks (range 2.0–20.6) for patients who received no corticosteroid treatment or no steroid dose increase (including a patient with cerebral metastasis) (n = 6) vs. 8.6 weeks (4.3–55.1) in patients who received corticosteroids (n = 4). No significant difference was observed due to the small number of patients. Currently, immune-related hepatitis management recommendations8Haanen J.B.A.G. Carbonnel F. Robert C. Kerr K.M. Peters S. Larkin J. et al.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28: iv119-iv142Crossref PubMed Scopus (1304) Google Scholar, 9Puzanov I. Diab A. Abdallah K. Iii C.O.B. Brogdon C. Dadu R. et al.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immuno Ther Cancer. 2017; : 1-28PubMed Google Scholar, 10Information IS, Full US, Information P, Information IS. Immune-mediated adverse reactions management guide OPDIVO® is approved in 8 tumor types n.d.:62–5.Google Scholar are based on a colitis model and recommend a high dose of steroids (from 1 to 2 mg/kg/d) for grade 3–4 or persistent grade 2 hepatitis (more than 1–2 weeks). If no response to corticosteroids is obtained within 2–3 days, mycophenolate should be considered. Use of steroids is logical based on the mechanisms of immune-related colitis, highly reminiscent of idiopathic intestinal inflammatory disease. However, corticosteroids might not be necessary for all toxicity-related to immune checkpoint inhibitors. Accordingly, the management of immune-related hepatitis appears heterogeneous, from abstention to corticosteroids or immunosuppressive drugs.8Haanen J.B.A.G. Carbonnel F. Robert C. Kerr K.M. Peters S. Larkin J. et al.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28: iv119-iv142Crossref PubMed Scopus (1304) Google Scholar, 9Puzanov I. Diab A. Abdallah K. Iii C.O.B. Brogdon C. Dadu R. et al.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immuno Ther Cancer. 2017; : 1-28PubMed Google Scholar, 10Information IS, Full US, Information P, Information IS. Immune-mediated adverse reactions management guide OPDIVO® is approved in 8 tumor types n.d.:62–5.Google Scholar The administration of corticosteroids is highly debatable in cases of drug-induced liver injury. Indeed, corticosteroids could induce severe adverse events and decrease the efficacy of immunotherapy. Based on these results, we agree with the authors’ conclusion[6]Zhang X. Ran Y. Wang K. Zhu Y. Li J. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: A meta-analysis.Drug Des Devel Ther. 2016; 10: 3153-3161Crossref PubMed Scopus (24) Google Scholar that management of immune-related hepatitis should be reconsidered, especially the indication for corticosteroids in this setting. Further controlled studies are needed to assess new management strategies for immune-related hepatitis. This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details. M.-L.G., B.B., C.Z., C.L. and M.B. had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. All authors made substantial contributions to the conception and design, the acquisition of data or analysis and the interpretation of data; contributed to drafting the article or revising it critically for important intellectual content; gave their final approval of the version to be published. We thank all the authors for their contribution. Download .pdf (.18 MB) Help with pdf files Supplementary data Download .pdf (.03 MB) Help with pdf files Supplementary Table S1